Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 dose-finding study in sporadic inclusion body myositis
NL-OMON41682Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of bimagrumab, sponsored by Novartis. Started Aug 2014; status: active, not recruiting.
02
Drugs
bimagrumab
Beyond the preview
Go deeper on NL-OMON41682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41682.